A Review Article on Vaccine Development and Therapeutics Approach Against SARS-CoV-2
Ankush Yadav1, Shubhangi Singh1, Vivek Srivastava2, *, Namrata Bardhan1, Saloni Gupta1, Paratpar Sarkar2, Harsimrut Kaur2
Identifiers and Pagination:Year: 2021
First Page: 117
Last Page: 138
Publisher Id: TOCOVIDJ-1-117
Article History:Received Date: 26/4/2021
Revision Received Date: 15/6/2021
Acceptance Date: 15/7/2021
Electronic publication date: 10/11/2021
Collection year: 2021
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
In December 2019, a novel coronavirus (COVID-19) unleashed an unprecedented and unanticipated pandemic, causing widespread concern. More than three million deaths have been documented since the first incidence of COVID-19 discovered in China. Several arduous efforts have been made by the governments of various countries worldwide to prevent and control the SARS-CoV-2 infection. This review article discusses an update on all kinds of therapeutic interventions currently applied or developed to treat SARS-CoV-2 condition, including the repurposing of drugs such as Remdesivir, Favipiravir, Ivermectin, etc. We also discuss CRISPR’s potential involvement in antiviral therapy, convalescent plasma therapy, and immunomodulators in combination to tackle the cytokine storms and present a comprehensive overview on many vaccines that have been created to date or are under trials, as well as their platforms and efficacy. Moreover, this article also discusses the mechanism of action of every therapeutic intervention.